Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement
Recruiting · NCT06461962 · Interventional (participants receive a specific treatment) · Lead sponsor: Oregon Health and Science University
View the official record on ClinicalTrials.gov →Interventions studied
Telehealth-CardiologyTreatment as Usual
What this trial is about
The goal of PEER-Heart is to implement and assess feasibility and preliminary effectiveness of a community peer-facilitated screening for methamphetamine-associated heart failure (MAHF) and linkage to evidence-based cardiology care for people who use methamphetamine in rural areas.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient-defined regular use of methamphetamine in the last year
- Any methamphetamine use in the past 30 days
- Age 18 years or older
- No client-reported diagnosis of heart failure
- Able to communicate in English
- Screen positive for potential methamphetamine-associated heart failure (MAHF) defined as B type natriuretic peptide (BNP) ≥50 pg/ml, or QRS width ≥120ms, or presence of any clinical heart failure symptoms
Exclusion criteria
- Self-reported engagement in medical care for heart failure in past 6 months.
- Actively taking medications for heart failure.
Where it is running
1 location listed across 1 US state.
- Oregon Health & Science University - Portland, Oregon, United States